A Phase III Double Blind Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer FLAURA 1